Skip to main content
. 2022 Dec 20;12(1):31. doi: 10.3390/jcm12010031

Table 2.

Clinical features of the sample based on type of tumor. A remarkable heterogeneity was observed in the sample. Group 1 tumor is defined as mesenchymal primary tumors, group 2 as primary tumors of the lung infiltrating the vertebrae and group 3 as vertebral metastases.

Alive (60 Months) Dead (60 Months) p Value Odds Ratio Conf. Interval p Value
Age, median–year (Mean ± SD) 42 ± 18.3 53 ± 15.6 0.0048 1.02 0.98–1.05 0.35
Gender, male—n (%) 20 (52%) 25 (73%) 0.067
Cardiological comorbitities—n (%) 6 (15%) 10 (29%) 0.16
Pneumological comorbitities—n (%) 2 (5.2%) 8 (23%) 0.039 3.09 0.38–24.76 0.12
Metabolic comorbitities—n (%) 4 (10%) 9 (26%) 0.12
Pre-Operative ASIA score 0.82
  • -

    A—n (%)

 1 (2.6%) 1 (2.9%)
  • -

    B—n (%)

 1 (2.6%) 3 (8.8%)
  • -

    C—n (%)

 7 (18%) 5 (14%)
  • -

    D—n (%)

 6 (15%) 6 (17%)
  • -

    E—n (%)

 23 (60%) 19 (55%)
Pre-operative chemotherapy—n (%) 13 (34%) 14 (41%) 0.54
Pre-operative Radiotherapy—n (%) 8 (21%) 12 (35%) 0.17
No. of involved vertebrae 0.84
  • -

    1—n (%)

 11 (28%) 12 (35%)
  • -

    2—n (%)

 11 (28%) 9 (26%)
  • -

    3—n (%)

 16 (42%) 13 (38%)
Associated lung resection—n (%) 7 (18%) 20 (58%) <0.0001 4.07 0.69–23.80 0.18
Surgical incisions 0.32
  • -

    Posterior Incision alone—n (%)

 13 (34%) 8 (23%)
  • -

    Posterior incision and thoracotomy—n (%)

 25 (65%) 26 (76%)
Tumors Group 0.001
  • -

    1—n (%)

 29 (76%) 11 (32%)
  • -

    2—n (%)

 3 (8%) 13 (38%) 1.86 0.24–14.30 0.55
  • -

    3—n (%)

 6 (16%) 10 (29%) 5.96 1.36–25.98 0.02
Grading 0.001 3.31 0.86–12.72 0.08
Surgical time—Hours (Medians IQR) 555 (461–660) 533.5(400–671) 0.87
ICU stay—Days (Medians IQR) 1.5 (1–4) 2.5 (1-6) 0.12
Hospital stay—Days (Medians IQR) 18.5 (14–22) 16.5 (13–23) 0.72
Age, median–year (Mean ± SD) 42 ± 18.3 53 ± 15.6 0.0048 1.02 0.98–1.05 0.35
Gender, male—n (%) 20 (52%) 25 (73%) 0.067
Cardiological comorbitities—n (%) 6 (15%) 10 (29%) 0.16
Pneumological comorbitities—n (%) 2 (5.2%) 8 (23%) 0.039 3.09 0.38–24.76 0.12
Metabolic comorbitities—n (%) 4 (10%) 9 (26%) 0.12
Pre-Operative ASIA score 0.82
  • -

    A–n(%)

 1 (2.6%) 1 (2.9%)
  • -

    B—n (%)

 1 (2.6%) 3 (8.8%)
  • -

    C—n (%)

 7 (18%) 5 (14%)
  • -

    D—n (%)

 6 (15%) 6 (17%)
  • -

    E—n (%)

 23 (60%) 19 (55%)
Pre-operative chemotherapy—n (%) 13 (34%) 14 (41%) 0.54
Pre-operative Radiotherapy—n (%) 8 (21%) 12 (35%) 0.17
No. of involved vertebrae 0.84
  • -

    1—n (%)

 11 (28%) 12 (35%)
  • -

    2—n (%)

 11 (28%) 9 (26%)
  • -

    3—n (%)

 16 (42%) 13 (38%)
Associated lung resection—n (%) 7 (18%) 20 (58%) <0.0001 4.07 0.69–23.80 0.18
Surgical incisions 0.32
  • -

    Posterior Incision alone—n (%)

 13 (34%) 8 (23%)
  • -

    Posterior incision and thoracotomy—n (%)

 25 (65%) 26 (76%)
Tumors Group 0.001
  • -

    1—n (%)

 29 (76%) 11 (32%)
  • -

    2—n (%)

 3 (7.8%) 13 (38%) 1.86 0.24–14.30 0.55
  • -

    3—n (%)

 6 (15%) 10 (29%) 5.96 1.36–25.98 0.02
Grading 0.001 3.31 0.86–12.72 0.08
Surgical time—Hours (Medians IQR) 555 (461–660) 533.5 (400–671) 0.87
ICU stay—Days (Medians IQR) 1.5 (1–4) 2.5 (1–6) 0.12
Hospital stay—Days (Medians IQR) 18.5 (14–22) 16.5 (13–23) 0.72